medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (3)


New strategies for treating hepatic encephalopathy

Gómez-Gutiérrez C, Manzano-Robleda MC, Uribe M, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 12
Paginas: 409-411
Archivo PDF: 63.36 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25. Doi: 10.1038/nrgastro.2010.116.

  2. Liou IW. Management of end-stage liver disease. Med Clin North Am 2014; 98: 119-52. Doi: 10.1016/j.mcna.2013.09. 006.

  3. Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutierrez T, Villegas-Lopez FA, Mendez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013; 12: 74. Doi: 10.1186/1475-2891-12-74.

  4. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012; 27: 1329-35. Doi: 10.1111/j.1440-1746. 2012.07186.x.

  5. Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2013. Doi: 10.1016/j.cgh.2013.12.021.

  6. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-63. Doi: 10.1038/ ajg.2013.219.

  7. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58: 325-36. Doi: 10.1002/hep.26370.

  8. Smith W, Diaz GA, Lichter-Konecki U, Berry SA, Harding CO, McCandless SE, LeMons C, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013; 162: 1228-34, 34 e1. Doi: 10.1016/j.jpeds.2012.11.084.

  9. Guha M. Urea cycle disorder drug approved. Nat Biotechnol 2013; 31: 274. Doi: 10.1038/nbt0413-274.

  10. Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, Zupanets IA, et al. Randomized, doubleblind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014; 59: 1073-83. Doi: 10.1002/hep.26611.

  11. McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, Gargosky S, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51: 2077-85. Doi: 10.1002/hep.23589.

  12. Toapanta-Yanchapaxi L, Lopez-Velazquez JA, Uribe M, Mendez-Sanchez N. Minimal hepatic encephalopathy. Should we treat it? Ann Hepatol 2013; 12: 487-92.




2020     |     www.medigraphic.com